

**AMENDMENTS TO THE SPECIFICATION:**

Please amend the paragraph beginning at page 32, line 25, as follows:

We have previously shown that human sPLA<sub>2</sub>-IIA is dose-dependently inhibited by a pentapeptide sequence comprising residues 70-74 of the native sPLA<sub>2</sub>-IIA protein (<sup>70</sup>FLSKY<sup>74</sup>) SEQ ID NO:5 (Tseng, A., et al., (1996) J. Biol. Chem. 271:23992-23998). Because of the inherent flexibility of the linear peptide sequence, inhibition was weak in *in vitro* activity assays. We have recently designed two novel cyclic peptides (Church, W.B. et al.), cFLSYR and a cyclic peptide where F and Y are substituted with 2-naphthylalanine (c(2NapA)LS(2NapA)R). Both have shown significant improvement in potency over linear peptides. The potent stimulatory effect of exogenous sPLA<sub>2</sub>-IIA on prostate cancer cell number was completely blocked by the sPLA<sub>2</sub>-IIA inhibitor, cFLSYR (Fig. 2B) at all concentrations tested.